
There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

[http://eprints.gla.ac.uk/187250/](http://eprints.gla.ac.uk/187250/)

Deposited on 24 May 2019

Enlighten – Research publications by members of the University of Glasgow [http://eprints.gla.ac.uk](http://eprints.gla.ac.uk)
Title: Living with cancer and multi-morbidity: the role of primary care

Authors: Dr David Nicholas Blanea*, Marta Lewandowskab

Affiliations:

a. General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow

b. Undergraduate Medical School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow

* Corresponding author: David N Blane, General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow, 1 Horselethill Road, Glasgow, G12 9LX, UK.

Email: David.blane@glasgow.ac.uk
Tel: 0141 330 5765

This is a non-final version of an article published in final form in Current Opinion in Supportive and Palliative Care
Purpose of review:
As more people live longer with cancer, the number of patients with cancer and multiple other chronic conditions (multi-morbidity) has increased. The presence of multi-morbidity impacts on all stages of cancer care, from prevention and early detection through to end of life care, but research into cancer and multi-morbidity is in its infancy. This review explores the impact of multi-morbidity on adults living with (and beyond) cancer, with particular attention paid to the role of primary care in supporting patients in this situation.

Recent findings:
Patterns of multi-morbidity vary depending on cancer type and stage, as well as population characteristics and available data (e.g. number of conditions assessed). Cancer survivors are at increased risk of developing other chronic conditions, due to a combination of shared risk factors (e.g. smoking and obesity), effects of cancer treatments, and psychosocial effects.

Summary:
Primary care has a central role to play in supporting multi-morbid adults living with cancer, providing holistic care of physical and mental well-being, while taking treatment burden and social circumstances into account. New models of person-centred and personalised cancer care include holistic needs assessments, care planning, treatment summaries, and cancer care reviews, and depend on improved communication between oncologists and primary care colleagues.

Keywords: cancer, multi-morbidity, co-morbidity, primary care, treatment burden
Introduction

Multi-morbidity is usually defined as the co-occurrence of two or more long-term conditions in any individual. The term promotes a person-centred approach, in contrast to the more disease-centred term “co-morbidity” where a patient is identified by their index condition and any additional health problems are considered co-morbidities. It is now widely recognised that most people with any long-term condition are more likely to have multi-morbidity than to have a single condition – multi-morbidity is the norm in chronic illness (1). Furthermore, the onset of multi-morbidity occurs roughly 10 to 15 years earlier in patients living in the most deprived areas compared to the most affluent (1). These observations have significant implications for health care, research and medical education, as outlined in the landmark 2012 Lancet paper on the epidemiology of multi-morbidity (1). Multi-morbidity matters because it is associated with adverse health outcomes, including higher mortality, poor quality of life, lower functional status, and higher rates of hospital admissions (2-4). Yet the optimal healthcare response to patients with multi-morbidity is unclear, and the majority of existing evidence is in populations of older people with little research on the larger number of people under 65 years of age with multi-morbidity (1, 5, 6).

In relation to cancer, the presence of multi-morbidity impacts on all stages of care, from prevention and early detection through to end of life care (7-10). Cancer prevention is complicated by multi-morbidity because many of the modifiable risk factors associated with the prevention of cancer (e.g. smoking, alcohol, poor diet, physical inactivity) are also linked to long-term conditions such as diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD), arthritis, and mental health conditions, the symptoms of which can make enacting behaviour change more challenging. Furthermore, many people have multiple unhealthy behaviours, with particular clustering in areas of socio-economic deprivation (11), adding further complexity (12).
Detecting cancer early can also be affected by multi-morbidity, with some patients having their cancer diagnosed earlier due to frequent contacts with health services, and others being diagnosed later if they attribute symptoms to comorbid conditions, as in the case of COPD and lung cancer (13).

The focus of this review, however, will be on the impact of multi-morbidity on adults living with (and beyond) cancer, with particular attention paid to the role of primary care in supporting patients in this situation. There is a complementary review in this issue which focusses on multi-morbidity in older adults with cancer (REF Corbett and Bridges paper).

We searched PubMed, EMBASE and Google Scholar using search terms in three broad categories relating to multi-morbidity, cancer, and primary care. We also used citation searching and articles from our personal collections to allow a thorough review of the subject. The majority of research articles we reviewed were published within the last 18 months and all were written in English.

Common patterns of multi-morbidity in adults living with cancer

Cancer incidence increases with age, as does the incidence of multi-morbidity. With ageing populations in most high-income countries, people are now more likely to develop cancer while already having other chronic conditions. Furthermore, with recent advances in cancer diagnosis and treatment, people are also living longer with cancer, and therefore more likely to develop other chronic diseases during their lifetime.

Figure 1 provides an illustration of the extent of multi-morbidity for people with any cancer, in a nationally representative sample of the Scottish population (1). Particularly common co-morbidities were painful conditions, depression, anxiety, coronary heart disease, diabetes, and COPD, and all of these were more prevalent in the most deprived decile compared to the most affluent.
More recently, Zemedikun et al analysed UK Biobank Data to establish patterns of multi-morbidity in adults aged 40 to 69 years (14). 19% of study participants had 2 or more chronic conditions, with hypertension, asthma and cancer being the three most common conditions (cancer prevalence was 8.3%). Cancer was associated with nine other conditions in their cluster analysis, including hypertension, asthma, anxiety, depression, eczema, irritable bowel syndrome, and migraine.

Patterns of multi-morbidity vary depending on cancer type and stage, as well as population characteristics and limitations of data (e.g. number of conditions assessed). For example, Williams et al assessed co-morbidities in older adults with different cancers in the US (15)*. Overall, 92% of participants reported one or more co-morbid condition, with a mean of 2.7 conditions (range 0 to 10). Approximately half of all patients reported arthritis and hypertension, but there were important differences in co-morbidities by cancer type. Circulatory problems, diabetes, heart disease, and depression were also common (affecting around 20%), in keeping with other studies that have explored co-morbidities associated with different cancers (16, 17).

The mechanisms underlying relationships between certain cancers and certain co-morbidities have been explored. Many cancers share common risk factors (smoking, obesity, alcohol) with conditions such as hypertension, cardiovascular disease (CVD), diabetes, and COPD, but there is recent evidence to suggest that certain chronic diseases themselves (e.g. diabetes and chronic kidney disease) may predispose to cancer (18).
Some pre-existing conditions also increase the risk of developing cancer treatment-related complications. For instance, patients with cardiovascular disease, diabetes or hypercholesterolaemia are more likely to develop cardiovascular side effects, especially left ventricular dysfunction, from anticancer therapy (19)*. Similarly, patients receiving androgen deprivation therapy in the treatment of prostate cancer have been shown to be at increased risk for developing diabetes (20).

Illness and treatment burden in multi-morbid adults living with cancer

There are several important implications of multi-morbidity for adults living with cancer. As noted above, multi-morbidity is associated with lower quality of life and poorer functional status and this can affect cancer treatment outcomes and therefore treatments offered. The concepts of illness and treatment burden may be helpful in guiding discussions and decision-making related to cancer treatment and support.

Illness burden refers to the “work” involved in living with a chronic illness and includes physical, emotional, social and existential elements (10). This burden of illness is closely related to the number and severity of symptoms (e.g. pain, fatigue, breathlessness) that a patient is experiencing, but is also influenced by the patient’s capacity to understand and manage their different conditions and symptoms.

Treatment burden refers to the “work” that patients (and their families or carers) are asked to perform to respond to the requirements of their healthcare providers, as well as the impact that this work has on patient functioning and wellbeing (21). Research on treatment burden in patients with multi-morbidity has highlighted issues such as polypharmacy and complex medication regimes, fragmentation of care across different specialities, and challenges related to lifestyle changes and self-monitoring (22, 23).
Figure 2 shows an adaptation of the cumulative complexity model, a patient-centred framework that incorporates illness and treatment burdens but also emphasises the workload-capacity balance (24). Capacity in this context refers to the abilities, resources, or readiness to address the demands of illness and treatment. These resources include physical and mental functioning, socioeconomic resources, social support, literacy, and attitudes/beliefs (24).

A recent qualitative systematic review and synthesis of evidence on the experience of cancer and co-morbid illness suggests there is still considerable room for improvement in addressing the workload-capacity balance to better support multi-morbid adults living with cancer (25)**. The authors identified five key themes from the 31 included studies: 1) the interaction and impact of cancer and co-morbidity (which affected not only quality of life and recovery, but also treatment decisions); 2) the complex symptom burden and experience (which was variable and mediated for some by cancer stage and severity but also led to blurring of symptoms and attribution difficulties for others); 3) illness expectations and identity when facing complex illness (which was influenced by past experience of illness as well as notions of ageing and expectations of ailing health and function); 4) managing medications and self-management (which emphasised the need for shared care and resources to support self-management); and 5) the role of primary and secondary care in meeting survivorship needs (which highlighted the at times fragmented experience of care).

Some of these findings reflect wider trends in cancer treatment, such as the shift towards shorter inpatient stays and a greater emphasis on management (and self-management) closer to home, with patients and carers encouraged to be more responsible for their care. Furthermore, the increasing use of oral chemotherapy has presented new challenges for
patients and healthcare providers (26). Oral regimens can be complex, comprised of multiple medications with varying dosages and instructions, and requiring patients and primary care practitioners to recognise side effects and potential interactions.

Common side effects of oral chemotherapy treatments include nausea, fatigue, diarrhoea, oral mucositis, sleep disturbance, skin conditions (e.g. rashes, blisters, dry skin), and neuropathy. Managing these at home may require dose modifications, interruptions, discontinuing treatment, or admission to hospital, all of which require communication between patients and their healthcare providers, ideally in primary and secondary care.

Patients with multi-morbidity are more likely to be prescribed multiple medications (known as polypharmacy) and primary care practitioners are well placed to assess polypharmacy and identify potentially inappropriate medications (PIMs), with a high risk-to-benefit ratio. A recent study of older patients with breast and colorectal cancer found that roughly 30% were on PIMs (27). A similar study found even higher rates of PIMs (over 65% for patients with colorectal cancer) and significant associations with increased healthcare utilisation and higher costs (28).

The role of primary care in supporting multi-morbid adults living with cancer

The role of primary care in supporting patients living with and beyond cancer was well summarised in a 2018 review in this journal, which emphasised the strengths of primary care as contact, comprehensiveness, continuity and coordination (29). These four pillars of primary care are particularly important in the context of adults with multi-morbidity, who account for over half of all GP consultations and nearly 80% of prescriptions (30).

Despite these apparent strengths, it is well recognised that GP input during cancer treatment and survivorship phases is highly variable, both within and between countries (31). Rubin et al outlined the following areas as being particularly important for primary care practitioners
(PCPs) to optimise care: long-term and late effects of cancer treatment; psychosocial
effects; detection of recurrence; prevention; and models to deliver survivorship care (31). All
of these aspects of care are potentially more complex in the presence of multi-morbidity.

Knowledge of the long-term and late effects of cancer treatment was recognised as one of
several learning gap for PCPs in relation to cancer survivorship care (32). While primary
care practitioners (GPs and practice nurses) may be well used to supporting adults with
multi-morbidity, providing holistic care of physical and mental well-being, and taking social
circumstances into account, it is clear that people living with cancer have unmet physical,
psychosocial and spiritual needs (33, 34).

Psychosocial needs of multi-morbid patients with cancer were explored in a qualitative study
from Australia which showed how multi-morbid illness representations can influence self-
management (35)*. Most of the study participants – who had cancer and anxiety/depression
– viewed the conditions as intertwined. A range of cancer-related consequences were
perceived as causing anxiety/depression, including visible scars from treatment, physical
disabilities, hair loss, inability to work, fertility difficulties, and loss of independence (35)*.

The fear of cancer recurrence (FCR) was common and manageable for most, but for some
people it could become debilitating, resulting in unhelpful coping behaviours (e.g. becoming
“engrossed in Dr Google”) and worsening their anxiety/depression. This is in keeping with
the growing body of research on FCR (36, 37), suggesting that screening for and monitoring
of psychosocial effects (such as FCR) should be a routine part of cancer care reviews in
primary care.

The role of primary care in the preventive care of cancer survivors is also gaining increasing
attention (38). Preventive care relates to the prevention of morbidity and premature mortality
in individuals and is traditionally considered in terms of primary, secondary and tertiary
prevention. For cancer survivors, the prevention of further cancers and cardiovascular
disease are priorities. One recent study found that approximately 25% of older adults (≥65
years) and 11% of younger adults had a history of prior cancer, with most of these new
cancers diagnosed in different anatomic locations (39)*. Cancer survivors are at increased
risk of CVD, due to a combination of shared risk factors (e.g. smoking and obesity),
cardiotoxic effects of cancer treatments, and sub-optimal CVD prevention (40). Primary care
therefore has a key role in supporting health behaviour change related to smoking, alcohol,
diet and physical activity, as well as in optimising adherence to statins when indicated.

With regard to models of care for supporting multi-morbid adults living with cancer, there is
no consensus on the optimal approach, although all models include improved
communication between oncologists and primary care colleagues (41). Traditional follow-up
care based on routine appointments for years following treatment is now considered to be
neither sustainable nor effective (42). In the UK, recommendations for person-centred and
personalised (stratified) care for people affected by cancer include holistic needs
assessments, care planning, treatment summaries (including information about risk of
recurrence and known risks from treatments), access to educational ‘health and wellbeing’
events, and cancer care reviews (43).

Implications for future research
Supporting people with multiple chronic illnesses (multi-morbidity) to live well with (and
beyond) cancer requires robust evidence of what works, for whom, and in what
circumstances. At present, the majority of clinical practice cancer guidelines are derived
from clinical trials that exclude medically complex older adults (and those from poorer socio-
economic backgrounds (44)). This is often for rational scientific reasons – for instance, to
avoid interactions of other prescribed medications with the trial drug – but there are growing
calls for cancer trials to be more pragmatic and less exclusive (45, 46).
Research in patients with cancer and multi-morbidity poses several methodological challenges due to heterogeneous study populations, difficulties with recruitment and a variety of relevant outcome measures (47). Patient-reported outcome measures will increasingly inform the development of health services and other forms of support to limit the disruption to everyday lives of patients (and their carers) who are living with cancer (42, 48).

Conclusion

As more people live longer with cancer, the number of patients with cancer and multiple other chronic conditions will also increase. Primary care has a central role to play in supporting multi-morbid adults living with cancer, identifying physical, psychosocial and spiritual needs, and signposting to financial support if necessary.

It has been ten years since May and colleagues called for healthcare to be “minimally disruptive” to patients with chronic illness, tailoring treatment regimens to the realities of patients’ daily lives (23). Healthcare practitioners must take into account both workload demands and patient capacity when supporting patients living with cancer, asking questions such as: “Can you really do what we are asking you to do?” and “Do you think what we are asking you to do is the right thing for you?” (49)
Key points

- As people live longer with cancer, multi-morbidity is becoming the norm, with implications for health care, research and medical education.
- There is a strong social gradient in multi-morbidity, with onset 10-15 years earlier in more deprived areas.
- Health services need to consider illness and treatment burden, as well as patient’s existing capacity and resources, when discussing cancer treatments.
- New models of person-centred and personalised cancer care depend on improved communication between oncologists and primary care colleagues.

Acknowledgements

None

Financial support and sponsorship

DB is currently working on a grant funded by the Royal College of General Practitioners Scientific Foundation Board.

Conflicts of interest

None
References and recommended reading

Papers of particular interest, published within the 18 month period of review, have been highlighted as:

* of special interest
** of outstanding interest

15* This data linkage study highlights the impact of co-morbid conditions on adults with cancer: they are common, impair function, and are associated with increased risk of all-cause mortality.

19* UK editorial which introduces the emerging speciality of cardio-oncology and summarises its three distinct areas; the acute management of cardiovascular complications; the long-term screening of patients post-chemotherapy; and the planning of chemotherapeutic regimens in patients with established, or at high risk of, cardiovascular disease.

25** A qualitative systematic review and synthesis of evidence on the experience of cancer and co-morbid illness. The five themes identified in the review encapsulate the main challenges that multi-morbidity presents to high quality cancer care. They were: 1) the interaction and impact of cancer and co-morbidity; 2) the complex symptom burden and experience; 3) illness expectations and identity when facing complex illness; 4) managing medications and self-management; and 5) the role of primary and secondary care in meeting survivorship needs.

35* This qualitative study explored illness representations in patients with cancer and anxiety/depression. It highlights the common psycho-social impacts of cancer, such as effects on sense of identity and sexuality, and fear of cancer recurrence, as well as showing how patients' understandings of cancer and other conditions interact.
This study linked data from the US population-based Surveillance, Epidemiology, and End Results (SEER) program of cancer registries (1975-2013) for 740,990 persons newly diagnosed with cancer from January 2009 through December 2013. It shows that a substantial proportion of patients diagnosed with incident cancer in the United States have survived a prior cancer, and highlights that these patients are often excluded from clinical trials and underrepresented in observational research.


23. May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ. 2009;339:b2803.


49. Mair FS, May CR. Thinking about the burden of treatment. BMJ. 2014;349:g6680.